Ensysce Biosciences has announced its acquisition of Cy Biopharma, a clinical-stage company focused on novel neuroplastogenic therapies. The deal is supported by a significant private placement financing expected to raise over $60 million across two tranches. This strategic move positions the combined entity to advance new treatments for complex pain disorders with high unmet needs.
Strategic Acquisition and Financing Details
The transaction was bolstered by a concurrent private placement led by prominent investor Ally Bridge Group. An initial close is expected to secure approximately $21.5 million, with a follow-on tranche providing up to an additional $38.6 million. These funds are earmarked to advance the newly acquired clinical programs through key development milestones into 2028.
The acquisition was structured as a stock-for-stock merger, resulting in a new ownership distribution for the combined company. Former Cy Biopharma equity holders will own approximately 75% of the entity, with new investors holding about 17.5%. The transaction utilized Series C Preferred Stock, which will require stockholder approval for conversion to common stock.
Advancing a Novel Pain Treatment
The primary focus of the new funding is CY200, a promising therapy for Complex Regional Pain Syndrome (CRPS) Type 1. This severe chronic pain disorder currently has no approved treatments, making CY200 a potentially groundbreaking solution. The drug has already received Orphan Drug Designation from the U.S. Food and Drug Administration, providing key regulatory advantages.
Cy Biopharma's approach is distinguished by its focus on neuroplasticity to address the root causes of pain. Unlike traditional analgesics that manage symptoms, these therapies are designed to alter the underlying neurobiology of the disorder. This innovative strategy aims to deliver more durable and meaningful clinical benefits for patients suffering from severe chronic pain.
Leadership and Future Outlook
As part of the integration, Cy Biopharma's Founder and CEO, James Morrison, will assume the role of President at Ensysce. He will also be appointed to the company's Board of Directors, ensuring leadership continuity for the acquired programs. This move strategically combines the expertise of both management teams to guide the company's expanded pipeline.
Leadership from both companies expressed strong optimism regarding the merger's potential to create significant value. Ensysce CEO Dr. Lynn Kirkpatrick highlighted the compelling clinical data for CY200 and its potential for stockholders. James Morrison noted the transaction provides the necessary capital and public platform to execute their mission for patients.
While advancing Cy Biopharma's assets, Ensysce will continue developing its proprietary opioid safety platforms. The company's PF614-MPAR program, a novel approach to preventing opioid abuse, will proceed with financial support from the National Institute on Drug Abuse. This demonstrates a continued commitment to its original mission of creating safer pain management solutions.
This acquisition marks a transformative step for Ensysce Biosciences, significantly expanding its pipeline into non-opioid pain treatments. The substantial new funding and integrated leadership provide a robust foundation for advancing CY200 through critical clinical trials. Ultimately, the merger holds the promise of delivering innovative therapies to patients with debilitating pain conditions who currently lack effective options.